116 related articles for article (PubMed ID: 38921803)
21. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
[TBL] [Abstract][Full Text] [Related]
22. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
medRxiv; 2021 Aug; ():. PubMed ID: 34100029
[TBL] [Abstract][Full Text] [Related]
23. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases.
Mrak D; Kartnig F; Sieghart D; Simader E; Radner H; Mandl P; Göschl L; Hofer P; Deimel T; Gessl I; Kain R; Winkler S; Smolen JS; Perkmann T; Haslacher H; Aletaha D; Heinz LX; Bonelli M
J Autoimmun; 2023 Feb; 135():102981. PubMed ID: 36706534
[TBL] [Abstract][Full Text] [Related]
24. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
25. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
[TBL] [Abstract][Full Text] [Related]
26. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989
[TBL] [Abstract][Full Text] [Related]
27. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
[TBL] [Abstract][Full Text] [Related]
28. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.
Shirata M; Ito I; Tanaka M; Murata K; Murakami K; Ikeda H; Oi I; Hamao N; Nishioka K; Hayashi Y; Nagao M; Hashimoto M; Ito H; Ueno H; Morinobu A; Hirai T
Clin Exp Med; 2023 Dec; 23(8):4707-4720. PubMed ID: 37582911
[TBL] [Abstract][Full Text] [Related]
29. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
[TBL] [Abstract][Full Text] [Related]
30. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
[TBL] [Abstract][Full Text] [Related]
31. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
32. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants.
Vogrig M; Berger AE; Bourlet T; Waeckel L; Haccourt A; Chanavat A; Hupin D; Roche F; Botelho-Nevers E; Pozzetto B; Paul S
J Clin Immunol; 2023 Jan; 43(1):31-45. PubMed ID: 36006568
[TBL] [Abstract][Full Text] [Related]
34. Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens.
Culebras E; Martínez M; Novella C; León JM; Marcos E; Delgado-Iribarren A; Ríos E
Front Cell Infect Microbiol; 2024; 14():1370859. PubMed ID: 38572317
[TBL] [Abstract][Full Text] [Related]
35. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
36. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
37. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
Geldof J; Truyens M; Sabino J; Ferrante M; Lambert J; Lapeere H; Hillary T; Van Laethem A; de Vlam K; Verschueren P; Padalko E; Lobaton T; Vermeire S
Front Immunol; 2023; 14():1126351. PubMed ID: 36936974
[TBL] [Abstract][Full Text] [Related]
39. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis.
Martin CA; Nazareth J; Jarkhi A; Pan D; Das M; Logan N; Scott S; Bryant L; Abeywickrama N; Adeoye O; Ahmed A; Asif A; Bandi S; George N; Gohar M; Gray LJ; Kaszuba R; Mangwani J; Martin M; Moorthy A; Renals V; Teece L; Vail D; Khunti K; Moss P; Tattersall A; Hallis B; Otter AD; Rowe C; Willett BJ; Haldar P; Cooper A; Pareek M
EClinicalMedicine; 2023 Apr; 58():101926. PubMed ID: 37034357
[TBL] [Abstract][Full Text] [Related]
40. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]